THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Tuesday, June 22, 2021
Dr. Guillermo Montalban-Bravo of The University of Texas MD Anderson Cancer Center's Department of Leukemia will lead this investigator-initiated Phase 1/2 experiment.
FREMONT, CA: Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company, developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced the start of a clinical trial to research seclidemstat, a novel Lysine-Specific Demethylase 1 (LSD1) inhibitor, as a potential treatment for hematologic cancers. Dr. Guillermo Montalban-Bravo of The University of Texas MD Anderson Cancer Center's Department of Leukemia will lead this investigator-initiated Phase 1/2 experiment.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The trial will be an open-label, dosage-finding, dose-expansion study to identify the maximum tolerated dose (MTD) of seclidemstat in combination with azacytidine as a therapy for Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). MDS and CMML are blood cancers that can lead to Acute Myeloid Leukemia (AML), a deadly leukemia. The trial was started due to strong preclinical findings showing that seclidemstat had anti-proliferative action in hematologic malignancies and synergy with azacytidine when administered together. Seclidemstat is a reversible, differentiated, oral inhibitor of LSD1, a critical enzyme linked to various cancers. Seclidemstat is being explored in several solid tumor trials, and preliminary results show that it has a tolerable safety profile and anti-tumor effectiveness.
Patients with MDS or CMML aged 18 and older will be enrolled in the dose-escalation stage of the Phase 1/2 trial. On days one through seven of each 28-day cycle, patients will receive 75 mg/m2 of azacytidine either Intravenously (IV) or Subcutaneously (SC) in conjunction with an increasing, twice-daily dose of seclidemstat provided as an oral tablet. Once the Safety Review Committee has determined the MTD of the combination, the study will move into a dose-expansion phase, in which more patients will be enrolled to confirm the safety and tolerability profile of seclidemstat in combination with azacytidine, as well as to collect efficacy data on overall response rate, duration of response, leukemia-free survival, relapse-free survival, and overall survival.
More in News